Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Neuromuscular Ultrasound Identification of Musculocutaneous Fasciculopathies in Neuralgic Amyotrophy
Zhitnitsky, Michael D., Carter, Julia T., Rizzo, Marco , Meiling, James B. , Meiling, James B , Zhitnitsky, Michael D.

Journal of Clinical Neuromuscular Disease | February 26, 2025 | Volume: 26 | Issue: 3 | Pages: 119-121

10.1097/cnd.0000000000000519 | PMID 40009415 Get It

Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes
Collin, Lindsay J. , Cushing‐Haugen, Kara L. , Terry, Kathryn L. , Goode, Ellen L. , Wu, Anna H. , Harris, Holly R. , Sasamoto, Naoko , Cramer, Daniel W. , Modugno, Francesmary , Elishaev, Esther , Moysich, Kirsten B. , Fasching, Peter A. , Pearce, Celeste Leigh , Menon, Usha , Gayther, Simon A. , Wentzensen, Nicolas , Goodman, Marc T. , George, Joshy , Talhouk, Aline , Anglesio, Michael S. , Ramus, Susan J. , Bowtell, David D.L. , Tworoger, Shelley S. , Schildkraut, Joellen M. , George, Joshy , Fu, Zhuxuan , Moysich, Kirsten , Fasching, Peter A , Pearce, Celeste Leigh , Menon, Usha , Gentry‐Maharaj, Aleksandra , Gayther, Simon A , Wentzensen, Nicolas , Goodman, Marc T , George, Joshy , Talhouk, Aline , Anglesio, Michael S , Ramus, Susan J , Bowtell, David D , Tworoger, Shelley S , Schildkraut, Joellen M , Webb, Penelope M , Doherty, Jennifer A , Cramer, Daniel W , Modugno, Francesmary , Harris, Holly R , Elishaev, Esther , Cushing-Haugen, Kara L , Fu, Zhuxuan , Webb, Penelope M. , Doherty, Jennifer A.

Cancer Epidemiology, Biomarkers & Prevention | February 26, 2025 | Volume: 34 | Issue: 5 | Pages: 762-773

10.1158/1055-9965.epi-24-1143 | PMID 40009771 Get It

Abstract Background: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology of HGSC. We investigated associations between different epidemiologic risk factors and HGSC molecular subtypes. Methods: We pooled data from 11 case–control studies with epidemiologic and tumor gene expression data from custom NanoString CodeSets developed through a collaboration within the Ovarian Tumor Tissue Analysis consortium. The PrOTYPE-validated NanoString-based 55-gene classifier was used to assign HGSC gene expression subtypes. We examined associations between epidemiologic factors and HGSC subtypes in 2,070 cases and 16,633 controls using multivariable-adjusted polytomous regression models. Results: Among the 2,070 HGSC cases, 556 (27%) were classified as C1.MES, 340 (16%) as C5.PRO, 538 (26%) as C2.IMM, and 636 (31%) as C4.DIF. The key factors, including oral contraceptive use, parity, breastfeeding, and family history of ovarian cancer, were similarly associated with all subtypes. Heterogeneity was observed for several factors. Former smoking [OR = 1.25; 95% confidence interval (CI) = 1.03, 1.51] and genital powder use (OR = 1.42; 95% CI = 1.08, 1.86) were uniquely associated with C2.IMM. History of endometriosis was associated with C5.PRO (OR = 1.46; 95% CI = 0.98, 2.16) and C4.DIF (OR = 1.27; 95% CI = 0.94, 1.71) only. Family history of breast cancer (OR = 1.44; 95% CI = 1.16, 1.78) and current smoking (OR = 1.40; 95% CI = 1.11, 1.76) were associated with C4.DIF only. Conclusions: This study observed heterogeneous associations of epidemiologic and modifiable factors with HGSC molecular subtypes. Impact: The different patterns of associations may provide key information about the etiology of the four subtypes.
Environmental factors in polymyalgia rheumatica and giant cell arteritis
Mantello, Ester, Matteson, Eric L. , Hysa, Elvis , Gotelli, Emanuele , Campitiello, Rosanna , Cutolo, Carlo Alberto

Journal of Environmental Rheumatology | February 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/jer/ztobhu Get It

Weight Loss Before Total Hip Arthroplasty Was Not Associated with Decreased Postoperative Risks
Grimm, Jessica A. , Hannon, Charles P. , Bedard, Nicholas A. , Berry, Daniel J. , Abdel, Matthew P. , Seward, Michael W , Grimm, Jessica A , Hannon, Charles P , Berry, Daniel J , Abdel, Matthew P , Bedard, Nicholas A

Journal of Bone and Joint Surgery | February 26, 2025 | Volume: 107 | Issue: 8 | Pages: 849-857

10.2106/jbjs.24.01110 | PMID 40009699 Get It

Background: Many surgeons use body mass index (BMI) cutoffs when offering total hip arthroplasty (THA). However, little is known about who loses weight before THA, and if weight loss improves outcomes. This study determined how many patients lost weight before primary THA, identified predictors of preoperative weight loss, and evaluated whether preoperative weight loss was associated with improved outcomes. Methods: Among 53,038 primary THAs that were performed between 2002 and 2019, we identified 2,463 patients who had a BMI of ≥30 kg/m 2 (measured 1 to 24 months before surgery) and had their weight measured at the time of surgery. The mean age was 66 years; 47% were women. The mean BMI was 35 kg/m 2 . Nonparametric models evaluated potential associations with weight loss. Univariable and multivariable logistic regression and Cox proportional hazards models evaluated the impact of preoperative weight change on hospital length of stay, discharge disposition, operative time, periprosthetic joint infection (PJI), complications, revision, and reoperation. The mean follow-up was 5 years. Results: Overall, 17% of the patients gained >5 pounds (2.27 kg), 38% maintained their weight, 16% lost 5 to <10 pounds (4.54 kg), 17% lost 10 to <20 pounds (9.07 kg), and 12% lost ≥20 pounds before THA. Only 28% of patients with a preoperative BMI of ≥40 kg/m 2 achieved a BMI of <40 kg/m 2 by the time of surgery; those who did required a mean of 1.3 years to lose the weight. In multivariable analyses, there were no significant improvements in operative time, length of stay, and discharge disposition, or survivorship free of PJI, complication, revision, or reoperation for any weight-loss category when compared with those who maintained their weight. Conclusions: Only 12% of patients lost ≥20 pounds, and only 28% of patients with a BMI of ≥40 kg/m 2 achieved a BMI of <40 kg/m 2 before primary THA. There was no decrease in complications, revisions, or reoperations for any preoperative weight-loss category when compared with those who maintained their weight. While weight loss benefits overall health, the results of this study call into question whether preoperative weight loss alone is enough to reduce postoperative complications for most patients. Level of Evidence: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
The New CMS Measure of Excessive Radiation Dose or Inadequate Image Quality in CT: Issues and Ambiguities—Perspectives From an AAPM-Commissioned Panel
Wells, Jered R. , Christianson, Olav, Gingold, Eric L. , Jacobs, Jurgen, Boedeker, Kirsten , Ramírez-Giraldo, Juan Carlos , Yu, Lifeng , Gress, Dustin A. , Yu, Lifeng , McNitt‐Gray, Michael F. , Samei, Ehsan

American Journal of Roentgenology | February 26, 2025 | Volume: 224 | Issue: 5 | Pages: No page available

10.2214/ajr.24.32458 | PMID 40008834 Get It

Analyzing Public Interest and Information in Superficial Radiation Therapy for Keratinocyte Carcinomas: Google Trends 2004–2024
Jing, Frank Z., Vidal, Nahid Y. , O'Hern, Keegan , Jing, Frank Z. , O’Hern, Keegan

Dermatologic Surgery | February 26, 2025 | Volume: 51 | Issue: 7 | Pages: 722-723

10.1097/dss.0000000000004589 | PMID 40008793 Get It

Uremic Toxins, CKD, and Cognitive Dysfunction
Andrews, Taylor , Day, Gregory S. , Irani, Sarosh R. , Kanekiyo, Takahisa , Hickson, LaTonya J. , Andrews, Taylor D , Irani, Sarosh R , Hickson, LaTonya J , Day, Gregory S

Journal of the American Society of Nephrology | February 26, 2025 | Volume: 36 | Issue: 6 | Pages: 1208-1226

10.1681/asn.0000000675 | PMID 40009460 Get It

Cognitive impairment involves alterations to one's cognitive status that affects everyday life. Individuals with CKD, and particularly kidney failure, experience higher rates of cognitive impairment (20%–70%) compared with the general population. The highest prevalence is described in kidney failure such that dialysis-dependent patients have twice the prevalence of age-matched controls. In the past 5 years, the number of investigations examining the “kidney-brain axis,” mechanisms of CKD-related cognitive impairment, and potential therapeutics have exponentially increased. This review article summarizes recent literature on direct and indirect effects of CKD-associated cognitive impairment with emphasis on uremic toxins; brain injury mechanisms; overlap between CKD-associated cognitive impairment, Alzheimer's disease, and other neurodegenerative diseases. Reviewed therapeutic interventions include AST-120 (indoxyl sulfate absorbent), CH-223191 (aryl hydrocarbon receptor antagonist), triarylmethane-34 (Kca3.1-specific inhibitor), anakinra (IL-1R inhibitor), marimastat, exercise, supplements, and kidney transplantation. Special focus is placed on translational studies examining uremic toxin–associated pathogenic processes, including brain oxidative stress, neuroinflammation, and blood-brain barrier dysfunction through in vitro and in vivo models of CKD-associated brain injury. Finally, future research directions are suggested, including targeting of cellular senescence abundance with senotherapeutics and capitalizing on anti-inflammatory effects of regenerative, cell-based therapeutics ( e.g ., mesenchymal stem cells and extracellular vesicles), and use of aged murine models. Collectively, CKD-associated cognitive impairment represents a prevalent condition for which remaining knowledge gaps exist, and scientific advancements are needed to preserve cognitive function and improve the lives of individuals with CKD.
Immediate Reduction in Left Ventricular Contractility After Mitral Transcatheter Edge‐to‐Edge Repair Is Associated With Lower Rates of Heart Failure Hospitalizations
Chen, Ke‐Wei , Chang, Jeng-Sheng , Sularz, Agata , Russo, Gerardo Lo , Chang, Shih‐Sheng , Liu, C H, Alkhouli, Mohamad , Chang, Ju-Hsin , Lo Russo, Gerardo , Saleh, Ghasaq, Chang, Shih-Sheng , Liu, Chia-Hao , Alkhouli, Mohamad , Sularz, Agata , Saleh, Ghasaq

Journal of the American Heart Association | February 26, 2025 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/jaha.124.037545 | PMID 40008509 Get It

Role of Biological Age in the Determination of Long‐Term Cause‐Specific Death Following Percutaneous Coronary Interventions
Singh, Mandeep , Friedman, Paul A. , Gulati, Rajiv , Sabbagh, Abdallah El , Lewis, B , Kanwar, Amrit , Raphael, Claire E. , Al‐Hijji, Mohammed , Attia, Zachi I. , Behfar, Atta , Kirkland, James L. , El Sabbagh, Abdallah , Lewis, Bradley R , Al-Hijji, Mohammed A , Behfar, Atta , Raphael, Claire , Attia, Zachi I

Journal of the American Heart Association | February 26, 2025 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/jaha.124.036876 | PMID 40008514 Get It

Background We tested whether biologic age, as estimated by deficits, functional impairments, or Age‐Gap or their combination, provide improved estimation of cause‐specific death as compared with chronological age. Methods Cardiovascular and noncardiovascular deficits, functional impairments, and Age‐Gap were prospectively collected in 535 patients aged ≥55 years undergoing percutaneous coronary interventions between August 1, 2014, and March 31, 2018. Age‐Gap was calculated as the difference between chronological age and age estimated by artificial intelligence ECG using a convolutional neural network. The full biological age model included deficits, functional impairments, and Age‐Gap >2 SD. A multivariable reduced model with the least number of variables was also created to provide a comparable C index to the full model. Results The average chronological age was 72.1±9.5 years, and there were 68% of men. During a median follow‐up of 2.61 years, 124 (23%) patients died. There was a modest correlation between Age‐Gap and biological age ( r =0.28 [95% CI, 0.20–0.35]; P <0.001). When modeled with chronologic age as a covariate, Age‐Gap predicted all‐cause (hazard ratio [HR], 1.07 [95% CI, 1.04–1.10]; P <0.001) and cardiovascular (HR, 1.07 [95% CI, 1.04–1.11]; P <0.001) mortality. As compared with chronological age, the full biological age model noted significant improvement in the prediction of long‐term overall (95% CI, 0.65–0.78), cardiovascular (95% CI, 0.69–0.77), and noncardiovascular (95% CI, 0.55–0.86) mortality. In the reduced models, most prognostic information for noncardiovascular mortality (C index: 0.79) was obtained by subjective difficulty in performing tasks, whereas the deficit‐based estimation predicted cardiovascular mortality (C index: 0.72). Conclusions Estimated biological age from deficits and functional impairments was superior to chronological age in predicting long‐term cause‐specific mortality following percutaneous coronary interventions.
Preclinical immunoPET imaging of thyroid-stimulating hormone receptor expression in thyroid cancer using [64Cu]Cu-NOTA-TSHR-Ab
Gleba, Justyna J., Copland, John A. , Fu, Wenhui , Parent, Ephraim E. , Gleba, Justyna J., Knight, Joshua A. , Cai, Hancheng

No container title available | February 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6074484/v1 Get It

Abstract Purpose The thyroid-stimulating hormone receptor (TSHR) is a cell-surface receptor predominantly expressed on benign and malignant thyroid cells, making it a viable target for developing radiotheranostics for metastatic thyroid cancer imaging and therapy. This study reports the radiosynthesis and preclinical evaluation of a 64Cu-labelled human antibody for positron emission tomography (PET) imaging of TSHR expression in thyroid cancer mouse models. Methods Human anti-TSHR recombinant antibody K1-70™ (TSHR-Ab) was conjugated with a bifunctional chelator, 2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA), and then labelled with [64Cu]Cu2+, yielding radiotracer [64Cu]Cu-NOTA-TSHR-Ab. The specificity and binding affinity of the radiotracer to TSHR-positive (THJ529TTSHR(+)) or wild-type (THJ529TWT) cells were assessed in vitro. A series of immnuoPET imaging with [64Cu]Cu-NOTA-TSHR-Ab were conducted in mice bearing dual-flank tumors (THJ529TWT on the left and THJ529TTSHR(+) on the right) at multiple time points (1, 2, 4, 18, 24, and 48 h) post-injection (p.i.). Radiotracer co-injection studies with varying doses of unlabelled (cold) TSHR-Ab (100, 50, 25, 0 µg) were studied to assess its effect on radiotracer uptake in tumors and off-target organs. Biodistribution and immunohistochemistry (IHC) were performed to verify the immnuoPET imaging results. Results [64Cu]Cu-NOTA-TSHR-Ab was synthesised with a radiochemical yield of 46.89 ± 3.74%, radiochemical purity of 98.77 ± 0.89%, and specific activity >1.42 GBq/mg (n = 5). In vitro cell studies demonstrated [64Cu]Cu-NOTA-TSHR-Ab had high specificity and nanomolar affinity for THJ529TTSHR(+) cells, with a dissociation constant (Kd) of 4.74 nM and an inhibition constant (Ki) of 0.92 nM. The immnuoPET imaging studies showed that the radiotracer could reach tumor quickly and showed high uptake in TSHR-positive thyroid tumors (SUVmax: 3.63 ± 0.42, 3.82 ± 0.44, and 4.09 ± 0.56 at 18, 24, and 48 h p.i., respectively). Co-injection with cold TSHR-Ab at doses ranging from 25 to 100 µg effectively reduced background signals, especially in spleen, liver, and bone. Notably, a dose of 25 µg cold TSHR-Ab reduced off-target signals without affecting tumor uptake. The biodistribution and IHC analyses further supported PET imaging findings. Conclusion TSHR-targeted radiotracer [64Cu]Cu-NOTA-TSHR-Ab was synthesized with high radiochemical purity. Our preclinical evaluation results demonstrate it is a promising radiotracer for PET imaging of TSHR-positive thyroid cancer, which may guide and monitor TSHR-targeted therapies. High radiotracer uptake in tumor, prolonged retention time, and favourable pharmacokinetics with the support of cold antibody co-injection, pave the way for the development of paired radiotherapeutics to treat TSHR-positive thyroid cancers.